A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

Amitesh Roy, Sook Park, David Cunningham, Yoon-Koo Kang, Yee Chao, Li-Tzong Chen, Charlotte Rees, H. Lim, J Tabernero, Francisco Ramos, Milan Kujundzic, M. Cardic, C. Yeh, Aimery de Gramont

    Research output: Contribution to journalArticlepeer-review

    91 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma'. Together they form a unique fingerprint.

    Medicine & Life Sciences